Electroanalytical Determination of Trimetazidine in Pharmaceuticals and Synthetic Urine Using an Anodically Treated Boron-Doped Diamond (BDD) Electrode and Square Wave Voltammetry (SWV)

Abstract

Trimetazidine dihydrochloride is an anti-ischemic agent widely used in the treatment of coronary artery disease, more specifically in the treatment of angina. Here is reported a simple and sensitive electroanalytical methodology for quantifying trimetazidine in pharmaceutical and synthetic urine samples using square-wave voltammetry. The influence of anodic and cathodic treatments on boron-doped diamond (BDD) was evaluated. The best results for trimetazidine were obtained using a BDD treated anodically at +3.0 V versus Ag(s)/AgCl(s)/Cl-(aq., saturated KCl) for 300 s in 0.1 mol L−1 H2SO4. The determination of trimetazidine was carried out in Britton-Robinson buffer at pH 3. Trimetazidine oxidation reveals two well-defined irreversible oxidation peaks. A calibration relationship was obtained from 0.35 mg L-1 to 2.6 mg L−1 (R2 = 0.997). Limits of detection and quantification for trimetazidine were 5.63 x 10−9 and 1.88 x 10−8 mol L−1, respectively. Recovery values were between 97 and 101 % and 96.8 and 99.8 % in pharmaceutical and synthetic urine.